| Lu, Ping J |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | N/A | 2500 | RoW | pathological stage | The First Affiliated Hospital of Xinxiang Medical College, AstraZeneca | Breast Cancer, Breast Carcinoma, Breast Tumor | 08/23 | 09/24 | | |
NCT06663735: Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma |
|
|
| Not yet recruiting | N/A | 400 | RoW | | The First Affiliated Hospital of Xinxiang Medical College | Uroepithelial Carcinoma | 07/25 | 07/25 | | |
